EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
News|Articles|February 2, 2012
Agitation From Sedation in Elderly
Geriatric patients can get agitated in response to sedation. How do you respond?
Advertisement
Watch for a paradoxical response to sedative-hypnotic agents in elderly patients. Old people occasionally become agitated, rather than sedated, after taking these drugs.
If this happens, a cup of coffee may calm them down.
Advertisement
Related to this article
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
Advertisement
Advertisement
Trending on Patient Care Online
1
5 FDA Decisions for Primary Care to Know from September 2026
2
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
3
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
4
Long-Term and Real-World Safety Data on Antipsychotic Agitation Therapy
5